Navigation Links
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
Date:11/1/2008

doses 12 hours apart, the concentration of ANA598 in plasma 12 hours after the second dose was 83 ug/mL, which substantially exceeds the level predicted to display antiviral potency. The data will be presented in a late-breaker poster titled "Results of a Phase I Safety, Tolerability and Pharmacokinetic Study of ANA598, a Non-Nucleoside NS5B Polymerase Inhibitor, in Healthy Volunteers", at 1:00 p.m. PST on Monday, November 3.

ANA598 Preclinical Data at AASLD Meeting

In addition to the results of the Phase I healthy volunteer study, Anadys is presenting additional data on the preclinical profile of ANA598 at the AASLD Meeting on Tuesday, November 4.

-- In a poster titled "In Vitro Studies Demonstrate that Combinations of Antiviral Agents that Include HCV Polymerase Inhibitor ANA598 have the Potential to Overcome Viral Resistance", Anadys will present the results of in vitro studies that show ANA598 to be synergistic with interferon-alpha, the protease inhibitor telaprevir (VX-950), and the nucleoside polymerase inhibitor PSI-6130 (the active agent of R7128). These studies also show that ANA598 retains activity against mutants known to confer resistance to other classes of direct antivirals, including protease inhibitors, nucleoside inhibitors and non-nucleosides that bind at the thumb site. Genotypic mutations resistant to ANA598 will be shown to be fully susceptible to interferon-alpha, telaprevir (VX-950) and PSI-6130. Data will also be presented demonstrating synergy between ANA598 and cytokines induced by ANA773, Anadys' TLR7 agonist oral prodrug, also in development for hepatitis C. These data strongly support the potential for ANA598 to be used in combination with multiple other agents approved or under investigation for hepatitis C.

-- In a poster titled "Antiviral Efficacy of the HCV RNA Polymerase Inhibitor ANA598 in the Chimpanzee Model of HCV Infection", Anadys will present data showing that ANA598 exhibits a substantial antivir
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
2. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
3. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
11. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013  Team Health Holdings ... the largest suppliers of outsourced healthcare professional staffing and ... the United States , today announced ... Annual Deutsche Bank Healthcare Conference held on May 29, ... begin at 8:00 AM eastern time.  Interested investors and ...
(Date:5/22/2013)... May 22, 2013  The Leukemia & Lymphoma Society ... Valor Biotherapeutics, LLC, a joint venture between ImmunGene and ... and a Phase I clinical trial for a novel ... by many patients with indolent lymphomas who do not ... Valor,s protein, IGN002, is a new class of biotherapeutics ...
(Date:5/22/2013)... , May 22, 2013 The new 13-valent ... as the previous version used prior to 2010, the ... Permanente study published today in Vaccine. The ... beginning in 2010 after a series of trials. These ... range of pneumococcal types than the previously used PCV7, ...
Breaking Medicine Technology:Team Health Holdings Inc. to Present at the 38th Annual Deutsche Bank Healthcare Conference 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4
... -- PharmaNet Development Group, Inc., a leading ... biotechnology, generic drug, and medical device industries, announced today ... tagline, "PharmaNet Works For You".  The new brand and ... provide intelligent solutions to accelerate drug development programs consistent ...
... Breathe Technologies, manufacturer of devices for respiratory insufficiency, ... A. Mastrovich as the new President and Chief Executive ... wealth of experience and strategic guidance," comments Chairman John ... role in building value within the homecare industry, and ...
Cached Medicine Technology:PharmaNet Launches New Brand Identity at Upcoming Industry Conferences 2Breathe Technologies Appoints New CEO 2
(Date:5/22/2013)... that bicyclists who wear helmets have an 88 percent ... Children,s Hospital found that simply having bicycle helmet laws ... and injuries for children younger than 16 who were ... study, conducted by William P. Meehan III, MD, Lois ... of Boston Children,s Hospital, and Christopher M. Fischer, MD, ...
(Date:5/22/2013)... MD (PRWEB) May 22, 2013 On a ... Lisa, spent a few hours watching “The Bourne Legacy” at ... While this may seem like a typical activity to many ... This little stretch of respite from their everyday reality has ... Seals Serving DC | MD | VA. , Life changed ...
(Date:5/22/2013)... The Muscular Dystrophy Association scored a huge ... annual Charlotte Muscle Team event held May 21 by ... with muscle disease. , "The Charlotte community really ... families,” said MDA Divisional Director Theresa Miller. “From the ... "Buddy" to make their night extra special, to the ...
(Date:5/22/2013)... Reporter , , WEDNESDAY, May 22 (HealthDay News) -- People ... likely to attempt suicide, whether or not they also ... a new study. "Clinicians who are seeing patients ... at increased risk of suicide," said study co-author Mark ... Resource and Evaluation Center in Ann Arbor, Mich. ...
(Date:5/22/2013)... Cedar Rapids, IA (PRWEB) May 22, 2013 ... inspirational theatre piece Handicap This! The performance promotes ... pursuing their dreams. The Handicap This! performance will be ... Linn Mar High School auditorium. Tickets for Handicap ... , Handicap This! helps audiences measure the level to ...
Breaking Medicine News(10 mins):Health News:Rate of bicycle-related fatalities significantly lower in states with helmet laws 2Health News:Military Family Finds Respite with Easter Seals 2Health News:Military Family Finds Respite with Easter Seals 3Health News:Charlotte Muscle Team Event Raises $300,000 in the Fight Against Muscle Disease 2Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 2Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 3Health News:Handicap This! Comes to Marion, Iowa 2
... ... ... Advocate Christ Medical Center and Hope Children’s Hospital was awarded the Morehead Apex Workplace ... the Ritz-Carlton in Charlotte, N.C. , , ,Christ Medical Center and Hope Children’s Hospital ...
... lead to new birth control for men , WEDNESDAY, April ... proteins called PLA2s play a vital role in sperm function ... The findings could improve understanding of male infertility and lead ... infertility. , In one study, Japanese researchers found that the ...
... ... except if the girls in the salon chair are battling cancer or other serious illness. Then, ... ... at the Tipperary Hair Salon in Beverly Hills, California, approximately 35 such girls and their sisters ...
... ... District to Develop a 100 Percent Lead Free Bubbler Retrofit Kit , ... Los Angeles, CA (Vocus) April 28, 2010 -- ... and chillers and a division of Acorn Engineering Company, announces a 100 percent lead-free bubbler ...
... 28, 2010 Many of the world,s leading experts in ... first-of-its-kind conference in Kansas City to change the way childhood ... hosted by Children,s Mercy Hospitals and Clinics, is to apply ... unique make-up of pediatric patients and improve outcomes. ...
... ... about supporting you after the sale when you believe you need to return an item. ... with complete confidence knowing that their purchase can be returned for a replacement or a ... ...
Cached Medicine News:Health News:Advocate Christ Medical Center Presented The 2009 Morehead Apex Workplace of Excellence Award 2Health News:Advocate Christ Medical Center Presented The 2009 Morehead Apex Workplace of Excellence Award 3Health News:Pediatric Patients and Siblings Enjoy Beverly Hills Beauty Makeover 2Health News:Pediatric Patients and Siblings Enjoy Beverly Hills Beauty Makeover 3Health News:The Acorn Aqua's Lead Free Bubbler 2Health News:Advances in personalized medicine take center stage 2Health News:National Allergy Supply, The Allergy Products Company Recommended By More Than 9,500 Doctors Nationwide, Announces 100% Unconditional Satisfaction Guarantee 2
All welded construction for strength and durability. Choice of stainless steel or chrome plated models. One forward leg with caster for increased mobility....
All welded construction for strength and durability. Choice of stainless steel or chrome plated models....
All welded construction for strength and durability. Choice of stainless steel or chrome plated models....
Ideal for surgical procedures, these portable stands fit into tight areas for easy instrument access. Designed for limited space environments. Adjustable height for comfortable use while sitting or s...
Medicine Products: